Identification of a <i>Candida albicans</i> Biofilm Inhibitor
- 1 Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Ohu University, Koriyama, Japan
Abstract
Candida albicans proliferates in the skin and oral cavity and is the causative agent of candida dermatitis and oral candidiasis. C. albicans is known to form biofilms on oral mucosa and denture surfaces. Formation of biofilms deteriorates the permeability of antifungal drugs, decreasing their effectiveness. Therefore, in this study, I identified a compound with inhibitory activity against C. albicans biofilm formation. Heat shock protein 90 was selected as the target protein, and a potential ligand for the same was extracted and identified as 2-(4-methylpiperazin-1-yl)cyclopentanol. C. albicans was then cultured with varying concentrations of this compound: 0 mmol/L, 0.63 mmol/l. 2.5 mmol/l, and 10 mmol/l, and biofilm formation was measured via crystal violet assay. The findings demonstrated that 2-(4-methylpiperazin-1-yl)cyclopentanol substantially inhibits biofilm formation when added at a concentration of 0.63 mmol/l or higher. It is suggested that C. albicans could be eliminated more efficiently using this compound in combination with the existing antifungal drug miconazole. Further, the compound may also be useful as a disinfectant for medical devices, such as catheters, to prevent the formation of C. albicans biofilms.
- Prasanna, K.R. (2012) Oral Candidiasis—A Review. Scholarly Journal of Medicine, 2, 26-30.
- Bart, J.K. and Maiken, C.A. (2015) Invasive Candidiasis. The New England Journal of Medicine, 373, 1445-1456. https://doi.org/10.1056/NEJMra1315399
- Benedict, K., Jackson, B.R., Chiller, T. and Beer, K.D. (2019) Estimation of Direct Healthcare Costs of Fungal Diseases in the United States. Clinical Infectious Diseases, 68, 1791-1797. https://doi.org/10.1093/cid/ciy776
- Darouiche, R.O. (1998) Oropharyngeal and Esophageal Candidiasis in Immunocompromised Patients: Treatment Issues. Clinical Infectious Diseases, 26, 259-274. https://doi.org/10.1086/516315
- Vazquez, J.A. (2010) Optimal Management of Oropharyngeal and Esophageal Candidiasis in Patients Living with HIV Infection. HIV/AIDS—Research and Palliative Care, 2, 89-101. https://doi.org/10.2147/HIV.S6660
- Harris, S.D. (2011) Hyphal Morphogenesis: An Evolutionary Perspective. Fungal Biology, 115, 475-484. https://doi.org/10.1016/j.funbio.2011.02.002
- Riquelme, M., Aguirre, J., Bartnicki-García, S., Braus, G.H., Feldbrügge, M., Fleig, M., et al. (2018) Fungal Morphogenesis, From the Polarized Growth of Hyphae to Complex Reproduction and Infection Structures. Microbiology and Molecular Biology Reviews, 82, e00068-17.
- Mayer, F.L., Wilson, D. and Hube, B. (2013) Candida albicans Pathogenicity Mechanisms. Virulence, 15, 119-128. https://doi.org/10.4161/viru.22913
- Krzysciak, W., Koscielniak, D., Papiez, M., Vyhouskaya, P., Zagorska, S.K., Kolodziej, I., et al. (2017) Effect of a Lactobacillus salivarius Probiotic on a Double-Species Streptococcus mutans and Candida albicans Caries Biofilm. Nutrients, 9, Article No. 1242. https://doi.org/10.3390/nu9111242
- Hall-Stoodley, L., Costerton, J.W. and Stoodley, P. (2004) Bacterial Biofilms: From the Natural Environment to Infectious Diseases. Nature Reviews Microbiology, 2, 95-108. https://doi.org/10.1038/nrmicro821
- Wall, G., Montelongo-Jauregui, D., Bonifacio, B.V., Lopez-Ribot, J.L. and Uppuluri, P. (2019) Candida albicans Biofilm Growth and Dispersal: Contributions to Pathogenesis. Current Opinion in Microbiology, 52, 1-6. https://doi.org/10.1016/j.mib.2019.04.001
- Mukherjee, P.K., Zhou, G., Munyon, R. and Ghannoum, M.A. (2005) Candida Biofilm: A Well-Designed Protected Environment. Medical Mycology 43, 191-208. https://doi.org/10.1080/13693780500107554